Compare WKHS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WKHS | NXL |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | WKHS | NXL |
|---|---|---|
| Price | $5.38 | $0.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $21.00 | $5.00 |
| AVG Volume (30 Days) | ★ 225.4K | 210.8K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $156,931.00 |
| Revenue This Year | $92.70 | $38.28 |
| Revenue Next Year | $34.00 | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.73 | N/A |
| 52 Week Low | $5.01 | $0.54 |
| 52 Week High | $118.50 | $3.87 |
| Indicator | WKHS | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 58.28 | 42.89 |
| Support Level | $5.20 | $0.71 |
| Resistance Level | $6.00 | $0.80 |
| Average True Range (ATR) | 0.40 | 0.08 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 35.35 | 60.74 |
Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric delivery trucks and drone systems, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.